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Abstract To study the nephrotoxic effects of occupa­
tional exposure to antineoplastic agents, the early renal 
effect parameters retinol-binding protein (RBP) and 
albumin (ALB) were determined in the urine of 11 
hospital workers involved in the preparation and ad­
ministration of antineoplastic agents and in 23 hospital 
workers not involved in drug handling, who served as 
nonexposed controls. No significant difference was 
found between the exposed group and the nonexposed 
control group with respect to the early renal effect 
parameters RBP and ALB. Although it was demon­
strated that the hospital workers were exposed to 
cyclophosphamide (CP) and probably other antineo- 
plastc agents, the results of the present study show that 
these exposure levels did not cause nephrotoxic effects.
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Introduction
Urinary proteins such as /?2-microglobulin, albumin 
(ALB), retinol-binding protein (RBP) and the urinary 
activity of enzymes such as alanine aminopeptidase, /?- 
galactosidase and N -acetyl-jS-D-glucosaminidase are 
early renal effect parameters that have proven useful for 
the early detection of nephrotoxicity. These parameters
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are widely used in occupational medicine for the detec­
tion of nephrotoxic effects in workers exposed to chem­
icals [16, 35]. They are also applied clinically to control 
nephrotoxic side-effects of drugs such as aminoglyco­
sides [3] and antineoplastic agents like cisplatin
[2, 3, 6, 8, 9,12,14,15,19, 30, 32,33, 35].
In a number of studies we have demonstrated that 
workers involved in the production, preparation and 
administration of antineoplastic agents are exposed to 
these drugs [5, 22-29]. The uptake was assessed by the 
determination of the parent drug or metabolite in the 
urine of the workers. Large differences were found in 
urinary excretion of cyclophosphamide (CP) between 
several groups, suggesting variable exposure levels 
[5,23, 24, 26, 28]. The question is whether these expo­
sure levels will cause nephrotoxic effects in the workers.
Recently, we presented the results of a study in 
which the urinary CP excretion was determined to­
gether with the analysis of chromosomal aberrations in 
peripheral blood lymphocytes of Dutch and Czech 
exposed and nonexposed hospital workers [26]. It was 
shown that chromosomal aberration frequencies were 
higher in the groups of exposed hospital workers than 
in their nonexposed controls. The highest amounts of 
CP were found in the urine samples of 11 exposed 
Czech hospital workers (0.1-2.9 |ig/24h). For a worst- 
case approach, this group and the corresponding 
nonexposed control group (n = 23) were selected for 
monitoring of early renal effects. Urinary ALB and 




Two groups were studied:
11 nurses, cleaning women and a lab technician involved in the 
preparation and administration of antineoplastic agents, all working 
in the same department of a hospital;
Table 1 Distribution by sex, age, exposure period and smoking habits in the exposed and nonexposed group of Czech hospital workers
aNumber of subjects (smokers and nonsmokers) 
hNumber of smokers
Sex Age Years of exposure Smokers
Male Female Mean Range Mean Range N h Number of cigarettes/day
Mean Range
Exposed 11 0 11 39 28-53 13 3-25 6 10 10
Nonexposed 23 3 20 44 27 59 4 17 13-20
23 control nurses, medical doctors, lab technicians and a cleaning 
woman not handling antineoplastic agents.
Six, age, profession, exposure period, smoking habits, alcohol use, 
illnesses, medicine use, inoculation and exposure to chemicals and 
X-rays were investigated by means of a questionnaire. From this, it 
appearred that the two groups were rather comparable. There were 
no indications that persons involved in this study could bring about 
a confounding effect. Some characteristics of the groups are shown 
in Table 1. Most of the workers handling antineoplastic agents used 
gloves, masks and special clothes. The agents were prepared in 
laminar down-flow cabinets. The amounts of the agents prepared 
and administered and the periods of handling were registered. CP, 
isophosphamide, cisplatin, 5-fluorouracil, methotrexate, cytarabine, 
doxorubicin, etoposide, vinblastine and vincristine were most fre­
quently prepared and administered.
Urine sampling and analysis
Total 24-h urine was collected in portions starting at the end of the 
preparation/administration of the drugs. The same urine samples 
were used as in a previous study for the determination pf CP [26]. 
Morning urine samples were used for analysis of RBP and ALB. 
Both proteins were determined by latex immunoassay [ 11] and were 
adjusted for dilution with the urinary creatinine (CREAT-U) con­
centration [35]. All parameters were analyzed within one run. The 
mean concentration and the duplicate precision (between brackets) 
of the determinations of the early renal parameters were: RBP 
126,4 iig/1 (9,6%); ALB 5.9 mg/1 (6.4%).
Statistical analysis
The nonnormal distributions of the renal effect parameters ALB and 
RBP were transformed logarithmically. Differences in both para­
meters between the exposed group and the nonexposed control 
group were tested with Student’s f-test. Correlations were quantified 
with the Pearson correlation coefficient, r. P-values (two-tailed) 
below 0.05 were considered to be of statistical significance. The 
statistical analysis were carried out on a personal computer using 
the InStat 1.1 software package.
Results
The mean concentrations of the renal effect parameters 
ALB and RBP in the exposed group and the nonex­
posed control group are presented in Table 2. No 
significant difference was observed between the two 
groups in the concentrations of these parameters. No
Table 2 Mean concentrations of the renal effect parameters al­
bumine (ÂLB) and retinol-binding protein (RBP) in the exposed and 
nonexposed group of Czech hospital workers
Parameter Geometric means (range) pa
Exposed (n = 11) Nonexposed
(h = 23)
ALB (mg/mol 0.44 (0.09-2.33) 0.30 (0.03-0.95) 0.27
CREAT-U)
RBP (jig/mol 7.9 (3.0-18.9) 8.8 (1.2-28.0) 0.71
CREAT-U)
aTwo-tailed f-test
correlation was found between the number of years of 
exposure and the urinary ALB (r =  0.31; P = 0.50) or 
RBP concentration (r — 0.25; P  = 0.59). In addition, 
ALB and RBP concentrations were not related 
(r =  0.33; P =  0.33). The effect of smoking was also 
investigated. To this end, the exposed group and the 
nonexposed control group were subdivided into 
smokers and non-smokers. Two-way analysis of vari­
ance (SAS General Linear Models procedure, software 
version 6.07) was used to study the influence of smok­
ing and exposure. No significant effect of smoking was 
found upon the urinary ALB and RBP excretion.
Discussion
Urinary renal effect parameters are widely used for the 
detection of early renal dysfunction in workers exposed 
to nephrotoxic chemicals such as organic solvents, 
heavy metals and silica [16,20]. In patients treated 
with some antineoplastic agents, nephrotoxic side-ef- 
fects are observed [2,3,6,8,9,12,14,15,19,30, 
32, 33, 35], The question is whether nephrotoxic effects 
occur in hospital workers who are occupationally ex­
posed to antineoplastic agents. Up to now, no such 
data have been published.
Several studies have shown that groups of hospital 
workers are exposed to antineoplastic agents
[4,5,13,17,23,24,26-29,34]. This was found by
measurement of the parent compound or metabolites 
in the urine of the workers. Pharmacokinetic studies
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have shown that large amounts of antineoplastic agents 
administered to patients are excreted unchanged in 
their urine [1,7,10,21,31]. These levels are much 
higher than those found in the urine of hospital 
workers involved in the preparation and administra­
tion of these agents. However, it remains unclear to 
what extent chronic exposure to low amounts of anti­
neoplastic agents will cause adverse health effects. In 
a previous study, we showed that occupational expo­
sure to these drugs may cause genetic effects [26]. It 
appeared that chromosomal aberration frequencies in 
peripheral blood lymphocytes of hospital workers 
handling antineoplastic agents were increased over 
those in their controls. The highest increase was ob­
served in the exposed smokers, suggesting an additive 
effect of exposure and smoking. Therefore, it is not 
impossible that these exposure levels may cause other 
health effects, such as nephrotoxicity. In order to detect 
possible nephrotoxic effects at an early stage, the excre­
tion of urinary ALB and RBP was determined.
Recently, it was found in a large study involving 
5670 people that urinary ALB concentrations were 
significantly higher in smokers than in nonsmokers 
[18]. Hence, it is reasonable to assume that smoking is 
a possible confounder. However, in our study no signi­
ficant effect of smoking on urinary ALB and RBP 
excretion was found. One explanation could be that 
our study was conducted in 34 hospital workers.
In conclusion, our results show no difference in 
urinary ALB and RBP excretion between the exposed 
group and the nonexposed control group of hospital 
workers. However, it should be noted that in our 
(pilot) study rather small groups were monitored. No 
increase in urinary RBP excretion indicates no tubular 
dysfunction. No increase in urinary ALB excretion and 
urinary RBP excretion indicates no tubular and no 
glomerular renal dysfunction. Although a previous 
study demonstrated that the hospital workers handling 
antineoplastic agents were exposed to one of these 
drugs, the results öf the present study indicate that 
these exposure levels do not result in clear nephrotoxic 
effects.
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